HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Sharon O'Kane Selected Research

human TGFB3 protein

9/2011Discovery and development of avotermin (recombinant human transforming growth factor beta 3): a new class of prophylactic therapeutic for the improvement of scarring.
7/2011Avotermin for scar improvement following scar revision surgery: a randomized, double-blind, within-patient, placebo-controlled, phase II clinical trial.
11/2010Scar-improving efficacy of avotermin administered into the wound margins of skin incisions as evaluated by a randomized, double-blind, placebo-controlled, phase II clinical trial.
9/2010Effects of avotermin (transforming growth factor β3) in a clinically relevant pig model of long, full-thickness incisional wounds.
1/2010Therapies with emerging evidence of efficacy: avotermin for the improvement of scarring.
8/2009Avotermin for the improvement of scar appearance: a new pharmaceutical in a new therapeutic area.
4/2009Prophylactic administration of avotermin for improvement of skin scarring: three double-blind, placebo-controlled, phase I/II studies.
4/2009A new approach for the prophylactic improvement of surgical scarring: avotermin (TGF beta 3).
11/2008New therapeutics for the prevention and reduction of scarring.
9/2008Avotermin: a novel antiscarring agent.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Sharon O'Kane Research Topics

Disease

17Cicatrix (Scar)
05/2013 - 05/2004
14Wounds and Injuries (Trauma)
05/2013 - 05/2002
1Inflammation (Inflammations)
05/2013
1Erythema
04/2009
1Cleft Palate (Palate, Cleft)
03/2007

Drug/Important Bio-Agent (IBA)

10human TGFB3 proteinIBA
09/2011 - 09/2008
6Pharmaceutical PreparationsIBA
08/2009 - 05/2004
5Transforming Growth Factor beta (TGF-beta)IBA
09/2011 - 05/2002
5Transforming Growth Factor beta3 (TGF beta 3)IBA
08/2009 - 03/2007
4CollagenIBA
07/2011 - 01/2003
3CytokinesIBA
05/2013 - 01/2010
3Prescription DrugsIBA
01/2010 - 05/2004
2Interleukin-10 (Interleukin 10)IBA
05/2013 - 12/2007
2Transforming Growth Factors (Transforming Growth Factor)IBA
07/2011 - 09/2010
2Proteins (Proteins, Gene)FDA Link
06/2011 - 09/2008
1Interleukin-4 (Interleukin 4)IBA
05/2013
1Biological ProductsIBA
04/2009
1Reducing AgentsIBA
12/2007
15-bromo-4-chloro-3-indolyl beta-galactoside (X-gal)IBA
03/2007
1AntibodiesIBA
07/2006
1Intercellular Signaling Peptides and Proteins (Growth Factors)IBA
05/2004
1Platelet-Derived Growth FactorIBA
05/2004
1Matrix Metalloproteinase 13IBA
01/2003
1Matrix Metalloproteinases (MMPs)IBA
01/2003

Therapy/Procedure

5Therapeutics
09/2011 - 09/2008
2Reoperation
07/2011 - 01/2010
2Intradermal Injections
11/2010 - 09/2008
1Injections
11/2010
1Electrodes (Electrode)
03/2010
1Occlusive Dressings (Occlusive Dressing)
03/2010